Reviewing Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY)

Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares Assembly Biosciences and CytoDyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-144.05%	-121.46%	-34.56%
CytoDyn	N/A	N/A	-76.70%

Volatility and Risk

Assembly Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, CytoDyn has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500.

Institutional & Insider Ownership

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 5.1% of CytoDyn shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.5% of CytoDyn shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Assembly Biosciences and CytoDyn, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	1	1	0	2.50
CytoDyn	0	0	0	0	0.00

Assembly Biosciences currently has a consensus price target of $35.00, indicating a potential upside of 153.62%. Given Assembly Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Assembly Biosciences is more favorable than CytoDyn.

Earnings and Valuation

This table compares Assembly Biosciences and CytoDyn”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$7.16 million	12.26	-$61.23 million	N/A	N/A
CytoDyn	$270,000.00	904.43	-$49.84 million	($0.01)	-19.89

CytoDyn has lower revenue, but higher earnings than Assembly Biosciences.

Summary

Assembly Biosciences beats CytoDyn on 8 of the 12 factors compared between the two stocks.

About Assembly Biosciences

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.